Literature DB >> 31723364

Amyloid PET Quantification Via End-to-End Training of a Deep Learning.

Ji-Young Kim1, Hoon Young Suh1, Hyun Gee Ryoo1, Dongkyu Oh1, Hongyoon Choi1, Jin Chul Paeng1, Gi Jeong Cheon1, Keon Wook Kang1, Dong Soo Lee1.   

Abstract

PURPOSE: Although quantification of amyloid positron emission tomography (PET) is important for evaluating patients with cognitive impairment, its routine clinical use is hampered by complicated preprocessing steps and required MRI. Here, we suggested a one-step quantification based on deep learning using native-space amyloid PET images of different radiotracers acquired from multiple centers.
METHODS: Amyloid PET data of the Alzheimer Disease Neuroimaging Initiative (ADNI) were used for this study. A training/validation consists of 850 florbetapir PET images. Three hundred sixty-six florbetapir and 89 florbetaben PET images were used as test sets to evaluate the model. Native-space amyloid PET images were used as inputs, and the outputs were standardized uptake value ratios (SUVRs) calculated by the conventional MR-based method.
RESULTS: The mean absolute errors (MAEs) of the composite SUVR were 0.040, 0.060, and 0.050 of training/validation and test sets for florbetapir PET and a test set for florbetaben PET, respectively. The agreement of amyloid positivity measured by Cohen's kappa for test sets of florbetapir and florbetaben PET were 0.87 and 0.89, respectively.
CONCLUSION: We suggest a one-step quantification method for amyloid PET via a deep learning model. The model is highly reliable to quantify the amyloid PET regardless of multicenter images and various radiotracers. © Korean Society of Nuclear Medicine 2019.

Entities:  

Keywords:  Alzheimer’s disease; Amyloid PET; Convolutional neural network; Deep learning; Quantification

Year:  2019        PMID: 31723364      PMCID: PMC6821901          DOI: 10.1007/s13139-019-00610-0

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  28 in total

1.  Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy.

Authors:  B J Bacskai; S T Kajdasz; R H Christie; C Carter; D Games; P Seubert; D Schenk; B T Hyman
Journal:  Nat Med       Date:  2001-03       Impact factor: 53.440

Review 2.  Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects.

Authors:  John Q Trojanowski; Hugo Vandeerstichele; Magdalena Korecka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Z Potter; Michael W Weiner; Clifford R Jack; William Jagust; Arthur W Toga; Virginia M-Y Lee; Leslie M Shaw
Journal:  Alzheimers Dement       Date:  2010-05       Impact factor: 21.566

3.  Generation of Structural MR Images from Amyloid PET: Application to MR-Less Quantification.

Authors:  Hongyoon Choi; Dong Soo Lee
Journal:  J Nucl Med       Date:  2017-12-07       Impact factor: 10.057

4.  The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET.

Authors:  William E Klunk; Robert A Koeppe; Julie C Price; Tammie L Benzinger; Michael D Devous; William J Jagust; Keith A Johnson; Chester A Mathis; Davneet Minhas; Michael J Pontecorvo; Christopher C Rowe; Daniel M Skovronsky; Mark A Mintun
Journal:  Alzheimers Dement       Date:  2014-10-28       Impact factor: 21.566

Review 5.  Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Dallas P Veitch; Michael W Weiner; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2018-10-13       Impact factor: 21.566

6.  Performance characteristics of amyloid PET with florbetapir F 18 in patients with alzheimer's disease and cognitively normal subjects.

Authors:  Abhinay D Joshi; Michael J Pontecorvo; Chrisopher M Clark; Alan P Carpenter; Danna L Jennings; Carl H Sadowsky; Lee P Adler; Karel D Kovnat; John P Seibyl; Anupa Arora; Krishnendu Saha; Jason D Burns; Mark J Lowrey; Mark A Mintun; Daniel M Skovronsky
Journal:  J Nucl Med       Date:  2012-02-13       Impact factor: 10.057

Review 7.  The Alzheimer's Disease Neuroimaging Initiative 2 PET Core: 2015.

Authors:  William J Jagust; Susan M Landau; Robert A Koeppe; Eric M Reiman; Kewei Chen; Chester A Mathis; Julie C Price; Norman L Foster; Angela Y Wang
Journal:  Alzheimers Dement       Date:  2015-07       Impact factor: 21.566

8.  Use of florbetapir-PET for imaging beta-amyloid pathology.

Authors:  Christopher M Clark; Julie A Schneider; Barry J Bedell; Thomas G Beach; Warren B Bilker; Mark A Mintun; Michael J Pontecorvo; Franz Hefti; Alan P Carpenter; Matthew L Flitter; Michael J Krautkramer; Hank F Kung; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Marwan N Sabbagh; Carl H Sadowsky; Eric P Reiman; P Eric M Reiman; Simone P Zehntner; Daniel M Skovronsky
Journal:  JAMA       Date:  2011-01-19       Impact factor: 56.272

9.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

Authors:  Christopher M Clark; Michael J Pontecorvo; Thomas G Beach; Barry J Bedell; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Eric M Reiman; Marwan N Sabbagh; Carl H Sadowsky; Julie A Schneider; Anupa Arora; Alan P Carpenter; Matthew L Flitter; Abhinay D Joshi; Michael J Krautkramer; Ming Lu; Mark A Mintun; Daniel M Skovronsky
Journal:  Lancet Neurol       Date:  2012-06-28       Impact factor: 44.182

Review 10.  Cerebral amyloid PET imaging in Alzheimer's disease.

Authors:  Clifford R Jack; Jorge R Barrio; Vladimir Kepe
Journal:  Acta Neuropathol       Date:  2013-10-08       Impact factor: 17.088

View more
  6 in total

1.  Tau Imaging: New Era of Neuroimaging for Alzheimer's Disease.

Authors:  Jae Seung Kim
Journal:  Nucl Med Mol Imaging       Date:  2020-07-27

2.  Deep-learning-based cardiac amyloidosis classification from early acquired pet images.

Authors:  Maria Filomena Santarelli; Dario Genovesi; Vincenzo Positano; Michele Scipioni; Giuseppe Vergaro; Brunella Favilli; Assuero Giorgetti; Michele Emdin; Luigi Landini; Paolo Marzullo
Journal:  Int J Cardiovasc Imaging       Date:  2021-02-16       Impact factor: 2.357

3.  Prediction of post-stroke cognitive impairment using brain FDG PET: deep learning-based approach.

Authors:  Reeree Lee; Hongyoon Choi; Kwang-Yeol Park; Jeong-Min Kim; Ju Won Seok
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-02       Impact factor: 9.236

4.  Boosting the diagnostic power of amyloid-β PET using a data-driven spatially informed classifier for decision support.

Authors:  Ashwin V Venkataraman; Wenjia Bai; Alex Whittington; James F Myers; Eugenii A Rabiner; Anne Lingford-Hughes; Paul M Matthews
Journal:  Alzheimers Res Ther       Date:  2021-11-10       Impact factor: 6.982

Review 5.  Quantification of amyloid PET for future clinical use: a state-of-the-art review.

Authors:  Hugh G Pemberton; Lyduine E Collij; Fiona Heeman; Ariane Bollack; Mahnaz Shekari; Gemma Salvadó; Isadora Lopes Alves; David Vallez Garcia; Mark Battle; Christopher Buckley; Andrew W Stephens; Santiago Bullich; Valentina Garibotto; Frederik Barkhof; Juan Domingo Gispert; Gill Farrar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-04-07       Impact factor: 10.057

6.  Development of Amyloid PET Analysis Pipeline Using Deep Learning-Based Brain MRI Segmentation-A Comparative Validation Study.

Authors:  Jiyeon Lee; Seunggyun Ha; Regina E Y Kim; Minho Lee; Donghyeon Kim; Hyun Kook Lim
Journal:  Diagnostics (Basel)       Date:  2022-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.